English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Advances in imaging and early cancer detection have increased interest inmagnetic resonance (MR) guided focused ultrasound (MRgFUS) technologies forcancer treatment. MRgFUS ablation treatments could reduce surgical risks,preserve organ tissue/function, and improve patient quality of life. However,surgical resection and histological analysis remain the gold standard to assesscancer treatment response. For non-invasive ablation therapies such as MRgFUS,the treatment response must be determined through MR imaging biomarkers.However, current MR biomarkers are inconclusive and have not been rigorouslyevaluated against histology via accurate registration. Existing registrationmethods rely on anatomical features to directly register in vivo MR andhistology. For MRgFUS applications in anatomies such as liver, kidney, orbreast, anatomical features independent from treatment features are ofteninsufficient to perform direct registration. We present a novel MR to histologyregistration workflow that utilizes intermediate imaging and does not rely onthese independent features. The presented workflow yields an overallregistration accuracy of 1.00 +/- 0.13 mm. The developed registration pipelineis used to evaluate a common MRgFUS treatment assessment biomarker againsthistology. Evaluating MR biomarkers against histology using this registrationpipeline will facilitate validating novel MRgFUS biomarkers to improvetreatment assessment without surgical intervention.

Histology to 3D In Vivo MR Registration for Volumetric Evaluation of MRgFUS Treatment Assessment Biomarkers